FrancophonIA/ELRC3.0 huggingface dataset:
English: Each tablet contains 41.7 mg lactose monohydrate.
Maltese: Kull pillola fiha 41.7 mg lactose monohydrate.
English: Each tablet contains 104 mg lactose monohydrate.
Maltese: Kull pillola fiha 104 mg lactose monohydrate.
English: Posterior reversible encephalopathy syndrome (PRES)
Maltese: Sindrome ta' enċefalopatija posterjuri riversibbli (PRES)
English: - The active substance is tacrolimus.
Maltese: - Is-sustanza attiva hija tacrolimus.
English: Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, amiodarone, danazol, ethinylestradiol, omeprazole and nefazodone.
Maltese: Interazzjonijiet aktar dgħajfa kienu osservati b'clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, amiodarone, danazol, ethinylestradiol, omeprazole, u nefazodone.
English: In adult liver, kidney, and heart transplant patients, values of 4.1 L/h, 6.7 L/h, and 3.9 L/h, respectively, have been observed.
Maltese: F'pazjenti adulti bi trapjant tal-fwied, kliewi, u qalb, kienu osservati valuri ta' 4.1 L/siegħa, 6.7 L/siegħa, u 3.9 L/siegħa,
English: Envarsus contains lactose.
Maltese: Envarsus fih lactose.
English: Envarsus contains the active substance tacrolimus.
Maltese: Envarsus fih is-sustanza attiva tacrolimus.
English: No specific antidote to tacrolimus therapy is available.
Maltese: Mhux disponibbli antidot speċifiku għal terapija ta' tacrolimus.
English: Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Maltese: Kura ta' rifjut ta' allograft reżistenti għal kura bi prodotti mediċinali immunosoppressivi oħra f'pazjenti adulti.
English: Other medicines and Envarsus
Maltese: Mediċini oħra u Envarsus
English: Envarsus is a once-a-day oral formulation of tacrolimus.
Maltese: Envarsus huwa formulazzjoni orali ta' darba kuljum ta' tacrolimus.
English: Tacrolimus is widely metabolised in the liver, primarily by the cytochrome P450-3A4.
Maltese: Tacrolimus huwa metabolizzat b'mod estensiv fil-fwied, primarjament miċ-ċitokromju P450-3A4.
English: Patients treated with tacrolimus have been reported to develop Epstein-Barr Virus (EBV)-associated lymphoproliferative disorders (see section 4.8).
Maltese: Pazjenti kkurati b'tacrolimus kienu irrappurtati li żviluppaw disturbi limfoproliferattivi assoċjati malVirus Epstein-Barr (EBV - Epstein-Barr Virus) (ara sezzjoni 4.8).
English: The efficacy and safety of Envarsus and Prograf, both in combination with mycophenolate mofetil (MMF) or mycophenolate sodium (MPS) and corticosteroids, were compared in 324 stable kidney transplant recipients.
Maltese: L-effikaċja u s-sigurtà ta' Envarsus u Prograf, it-tnejn flimkien ma' mycophenolate mofetil (MMF) jew mycophenolate sodium (MPS) u kortikosterojdi, kienu mqabbla f'324 riċevitur stabbli ta' trapjant tal-kliewi.
English: However, cases of spontaneous abortion have been reported.
Maltese: Madankollu, kienu rrappurtati każijiet ta' abort spontanju.
English: Systemically available tacrolimus is metabolised by hepatic CYP3A4.
Maltese: Tacrolimus disponibbli b'mod sistemiku huwa metabolizzat minn CYP3A4 tal-fwied.
English: The treatment failure rate using the same composite end-point with centrally read BPAR was 1.9% in the Envarsus group and 3.7% in the Prograf group (95% confidence interval [6.51%, 2.31%]).
Maltese: Ir-rata ta' falliment tal-kura bl-użu tal-istess punt finali kompost b'BPAR interpretat b'mod ċentrali kienet ta' 1.9% fil-grupp ta' Envarsus u ta' 3.7% fil-grupp ta' Prograf (intervall ta' kunfidenza ta' 95% [-6.51%, 2.31%]).
English: EU/1/14/935/004 EU/1/14/935/005 EU/1/14/935/006
Maltese: EU/1/14/935/005 EU/1/14/935/006
English: Only one of these has been shown in vitro to have immunosuppressive activity similar to that of tacrolimus.
Maltese: Wieħed minn dawn biss intwera in vitro li għandu attività immunosoppressiva simili għal dik ta' tacrolimus.
English: In clinical studies patients converted from twice daily Prograf were converted to Envarsus at 1:0.85 (mg:mg).
Maltese: Fi studji kliniċi pazjenti maqluba minn Prograf darbtejn kuljum ġew maqluba għal Envarsus f'1:0.85 (mg:mg).
English: Pharmacotherapeutic group: Immunosuppressants, calcineurin inhibitors, ATC code: L04AD02
Maltese: Immunosoppressanti, inibituri ta' calcineurin, Kodiċi ATC:
English: Experience with overdose is limited.
Maltese: Esperjenza ta' doża eċċessiva hija limitata.
English: Animal data have shown that tacrolimus could potentially decrease the clearance and increase the half-life of pentobarbital and antipyrine.
Maltese: Data mill-annimali turi li tacrolimus potenzjalment jista' jnaqqas it-tneħħija u jżid il-half-life ta' pentobarbital u antipyrine.
English: In vitro test results indicate that there is no risk of in vivo dose dumping related to alcohol intake.
Maltese: Riżultati ta' testijiet in vitro jindikaw li m'hemmx riskju ta' in vivo dose dumping relatat ma' konsum ta' alkoħol.
English: In addition, synergistic/additive nephrotoxic effects can occur.
Maltese: jistgħu jseħħu effetti nefrotossiċi sinerġistiċi/addittivi.
English: It is an immunosuppressant.
Maltese: pazjenti rispettiva taħt kura immunosoppressiva.
English: In man tacrolimus has been shown to be able to be absorbed throughout the gastrointestinal tract.
Maltese: Fil-bniedem tacrolimus intwera li jista' jigi assorbit mill-apparat gastrointestinali.
English: A combination of immunosuppressives, such as antilymphocytic antibodies (e.g. basiliximab, daclizumab), given concomitantly increases the risk of EBV-associated lymphoproliferative disorders.
Maltese: Taħlita ta' immunosoppressivi, bħal antikorpi antilimfoċitiċi (eż. basiliximab, daclizumab), mogħtija flimkien iżidu r-riskju ta' disturbi limfoproliferattivi assoċjati ma' EBV.
English: Clinically significant interactions have also been observed with phenobarbital.
Maltese: Interazzjonijiet klinikament sinifikanti kienu osservati wkoll b'phenobarbital.
English: The event rate for centrally read, biopsy-confirmed acute rejection (BPAR) during the 360-day study was 13.1% in the Envarsus group (N=268) and 13.5% in the Prograf group (N=275).
Maltese: 13.1% fil-grupp ta' Envarsus (N=268) u 13.5% fil-grupp ta' Prograf (N=275).
English: Unknown side effects (frequency not known): - Cases of pure red cell aplasia (a very severe reduction in red blood cell counts), - Agranulocytosis (a severely lowered number of white blood cells) - Haemolytic anaemia (decreased number of red blood cells due to abnormal breakdown) - Abnormality of the optic nerve (optic neuropathy)
Maltese: - Anemija emolitika (numru mnaqqas ta' ċelluli ħomor tad-demm minħabba tkissir mhux normali) - Anormalità tan-nerv ottiku (newropatija ottika)
English: Tacrolimus is also considerably metabolised in the intestinal wall.
Maltese: Tacrolimus huwa metabolizzat b'mod konsiderevoli wkoll fil-ħajt intestinali.
English: - The other excipients are hypromellose, lactose monohydrate, macrogol 6000, poloxamer 188, magnesium stearate, tartaric acid (E334), butylated hydroxytoluene (E321), dimethicone 350.
Maltese: magnesium stearate, tartaric acid (E334), butylated hydroxytoluene (E321), dimethicone 350.
English: There is limited experience in non-Caucasian patients and patients at elevated immunological risk (e.g. retransplantation, evidence of panel reactive antibodies, PRA).
Maltese: Hemm esperjenza limitata f'pazjenti mhux Kawkażi u f'pazjenti li għandhom riskju immunoloġiku elevat (eż. trapjant mill-ġdid, evidenza ta' serje ta' antikorpi reattivi, PRA - panel reactive antibodies).
English: Lymphoproliferative disorders and malignancies
Maltese: Disturbi limfoproliferattivi u tumuri malinni
English: Patients treated with immunosuppressants, including Envarsus, are at increased risk for infections including opportunistic infections (bacterial, fungal, viral and protozoal) such as BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML).
Maltese: Pazjenti kkurati b'immunosoppressanti, inkluż Envarsus, għandhom riskju akbar ta' infezzjonijiet inklużi infezzjonijiet opportunistiċi (ikkawżati minn batterja, fungi, virusis, u protożoa) bħal nefropatija assoċjata mal-virus BK u lewkoenċefalopatija multifokali progressiva (PML - progressive multifocal leukoencephalopathy) assoċjata mal-virus JC.
English: Tacrolimus is routinely administered in conjunction with other immunosuppressive agents in the initial post-operative period.
Maltese: Tacrolimus bħala rutina jingħata flimkien ma' sustanzi immunosoppressivi oħra fil-perjodu inizjali ta' wara l-operazzjoni.
English: The efficacy failure rate as measured by the composite endpoint of death, graft loss, centrally read BPAR and loss to follow-up was 18.3% in the Envarsus group and 19.6% in the Prograf group.
Maltese: Ir-rata ta' falliment tal effikaċja kif imkejjel mill-punti finali komposti ta' mewt, telf tat-trapjant, BPAR li jinqara ċentralment u telf ta' segwitu kienet ta' 18.3% fil-grupp ta' Envarsus u 19.6% fil-grupp ta' Prograf.
English: Envarsus is used in adults.
Maltese: Envarsus jintuża fl-adulti.
English: Skin and subcutaneous tissue disorders rash, pruritus, alopecias, acne, sweating increased dermatitis, photosensitivity toxic epidermal necrolysis (Lyell's syndrome)
Maltese: żieda fl-għaraq dermatite, fotosensittività nekrolisi tossika talepidermide (sindrome ta' Lyell)
English: Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ-interferon) and the expression of the interleukin-2 receptor.
Maltese: Tacrolimus irażżan l-attivazzjoni taċ-ċelluli T u l-proliferazzjoni taċ-ċelluli B dipendenti fuq iċ-ċelluli T-helper, kif ukoll il-formazzjoni ta' limfokini (bħal interleukins-2, -3, u γ-interferon) u l-espressjoni tar-riċettur ta' interleukin-2.
English: If signs of toxicity such as severe adverse reactions are noted (see section 4.8), the dose of Envarsus may need to be reduced.
Maltese: Jekk jiġu nnutati sinjali ta' tossiċità bħal reazzjonijiet avversi severi (ara sezzjoni 4.8), id-doża ta' Envarsus għandha mnejn tkun teħtieġ li tiġi mnaqqsa.
English: The frequency of adverse reactions is defined as follows: very common (≥1/10); common (≥1/100 to
Maltese: Lista ta' reazzjonijiet avversi f'tabella Il-frekwenza tar-reazzjonijiet avversi hija definita kif ġej: komuni ħafna (≥1/10), komuni (≥1/100 sa
English: Date of first authorisation: 18 July 2014 Date of latest renewal:
Maltese: Data tal-ewwel awtorizzazzjoni: 18 ta' Lulju 2014
English: Treatment-emergent fatal adverse events occurred in 1.8% of Envarsus patients and 2.5% of Prograf patients.
Maltese: Avvenimenti avversi fatali li ħarġu mal-kura seħħew f'1.8% tal-pazjenti fuq Envarsus u fi 2.5% tal pazjenti fuq Prograf.
English: EBV-Viral Capsid Antigen (VCA)-negative patients have been reported to have an increased risk of developing lymphoproliferative disorders.
Maltese: Pazjenti negattivi għal EBV-Viral Capsid Antigen (VCA) kienu rrappurtati li għandhom riskju akbar li jiżviluppaw disturbi limfoproliferattivi.
English: - if you have an alteration of the electrical activity of your heart called “QT prolongation”.
Maltese: - jekk għandek tibdil fl-attività elettrika ta' qalbek imsejjaħ “titwil tal-QT”.
English: Other potential interactions that may increase systemic exposure of tacrolimus include prokinetic agents (such as metoclopramide and cisapride), cimetidine and magnesium-aluminium-hydroxide.
Maltese: Interazzjonijiet potenzjali oħra li jistgħu jżidu l-esponiment sistemiku għal tacrolimus jinkludu sustanzi prokinetiċi (bħal metoclopramide u cisapride), cimetidine, u magnesium-aluminium hydroxide.
English: Effect of tacrolimus on the metabolism of other medicinal products
Maltese: Effett ta' tacrolimus fuq il-metaboliżmu ta' prodotti mediċinali oħra
English: Increased doses of tacrolimus, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes.
Maltese: Dożi miżjuda ta' tacrolimus, terapija supplimentari ta' kortikosterojdi, u l-introduzzjoni ta' korsijiet qosra ta' anti-korpi mono-/poliklonali kollha ntużaw biex jiġu mmaniġjati episodji ta' rifjut.
English: Each prolonged-release tablet contains 0.75 mg tacrolimus (as monohydrate).
Maltese: Kull pillola li terħi l-mediċina bil-mod fiha 0.75 mg tacrolimus (bħala monohydrate).
English: Pack sizes of 30, 60 and 90 prolonged-release tablets.
Maltese: Hemm disponibbli pakketti ta' 30, 60 u 90 pillola li jerħu l-mediċina bil-mod.
English: The efficacy and safety of Envarsus and Prograf, both in combination with mycophenolate mofetil (MMF), corticosteroids and IL-2 receptor antagonist as per the standard of care were compared in a randomised, double-blind, double-dummy study, in 543 de novo kidney transplant recipients.
Maltese: L-effikaċja u s-sigurtà ta' Envarsus u Prograf, it-tnejn flimkien ma' mycophenolate mofetil (MMF), kortikosterojdi u l-antagonist tar-riċettur IL-2 skont kura standard ġew imqabbla fi studju randomised, double-blind u double-dummy, f'543 riċevitur ġdid ta' trapjant tal-kliewi.
English: diltiazem and verapamil) - anti-arrhythmic substances (e.g. amiodarone) used to control arrhythmia (uneven beating of the heart)
Maltese: - sustanzi kontra l-arritmija (eż. amiodarone) użati għall-kontroll tal-arritmija (taħbit irregolari tal-qalb)
English: Tacrolimus is a highly potent immunosuppressive agent and has proven activity in both in vitro and in vivo experiments.
Maltese: Tacrolimus huwa sustanza immunosoppressiva qawwija ħafna u għandu attività ipprovata kemm f'esperimenti in vitro kif ukoll f'dawk in vivo.
English: 30 prolonged-release tablets 60 prolonged-release tablets 90 prolonged-release tablets
Maltese: 60 pillola li jerħu l-mediċina bil-mod 90 pillola li jerħu l-mediċina bil-mod
English: How to store Envarsus 6.
Maltese: Kif taħżen Envarsus 6.
English: Approximately 2% of the radioactivity was eliminated in the urine.
Maltese: Madwar 2% tar-radjuattività kienet eliminata fl-awrina.
English: Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES).
Maltese: Pazjenti kkurati b'tacrolimus kienu rrappurtati li żviluppaw sindrome ta' enċefalopatija posterjuri riversibbli (PRES - posterior reversible encephalopathy syndrome).
English: - The importance of avoiding inadvertent switching between tacrolimus containing products and the risk of under and overdosing if monitoring is inadequate.
Maltese: - L-importanza li tiġi evitata bidla involontarja bejn prodotti li fihom tacrolimus u r-riskju ta'
English: Care should be taken when converting patients from ciclosporin-based to tacrolimus-based therapy (see sections 4.4 and 4.5).
Maltese: Għandu jkun hemm attenzjoni meta pazjenti jinqalbu minn terapija ibbażata fuq ciclosporin għal terapija ibbażata fuq tacrolimus (ara sezzjonijiet 4.4 u 4.5).
English: PHARMACEUTICAL FORM
Maltese: Chiesi Farmaceutici
English: If PRES is diagnosed, adequate blood pressure and seizure control and immediate discontinuation of systemic tacrolimus is advised.
Maltese: huwa rakkomandat kontroll adegwat tal-pressjoni tad-demm u tal-aċċessjonijiet, u twaqqif immedjat ta' tacrolimus sistemiku.
English: In clinical practice, whole blood trough levels have generally been in the range of 5-20 ng/mL in kidney transplant patients in the early post-transplant period, and 5-15 ng/mL during subsequent maintenance therapy.
Maltese: Fil-prattika klinika, il-livelli l-aktar baxxi fid-demm sħiħ kienu ġeneralment fil-firxa ta' 5-20 ng/mL f'pazjenti bi trapjanti tal-kliewi fil-perjodu bikri ta' wara t-trapjant, u 5-15 ng/mL waqt terapija sussegwenti ta' manteniment.
English: Envarsus 0.75 mg prolonged-release tablets Envarsus 1 mg prolonged-release tablets Envarsus 4 mg prolonged-release tablets
Maltese: IL-PRODOTT MEDIĊINALI Envarsus 0.75 mg pilloli li jerħu l-mediċina bil-mod Envarsus 1 mg pilloli li jerħu l-mediċina bil-mod Envarsus 4 mg pilloli li jerħu l-mediċina bil-mod
English: Envarsus 0.75 mg prolonged-release tablets tacrolimus
Maltese: Envarsus 0.75 mg pilloli li jerħu l-mediċina bil-mod tacrolimus
English: Dose reduction may be necessary in patients with severe liver impairment (see section 4.2).
Maltese: F'pazjenti b'indeboliment sever tal-fwied jista' jkun meħtieġ tnaqqis fid-doża (ara sezzjoni 4.2).
English: Higher Cavg (~50%), reduced peak trough fluctuation (Cmax/Cmin) and a longer Tmax were seen for Envarsus when compared with both, tacrolimus immediate-release formulation (Prograf) and a tacrolimus once daily formulation (Advagraf).
Maltese: Cavg ogħla (~50%), varjazzjoni mnaqqsa ta' massimu sa minimu (Cmax/Cmin) u Tmax itwal dehru għal Envarsus meta mqabbla kemm ma' formulazzjoni ta' tacrolimus li terħi l-mediċina b'mod immedjat
English: The oral bioavailability of Envarsus was decreased when the medicinal product was administered after a meal; the extent of absorption was decreased by 55% and the maximum plasma concentration was decreased by 22% when taken directly after a high-fat meal.
Maltese: Il-bijodisponibiltà orali ta' Envarsus tnaqqset meta l-prodott mediċinali ingħata wara ikla; l-ammont ta' assorbiment kien imnaqqas b'55% u l-konċentrazzjoni massima fil-plażma kienet imnaqqsa b'22%
English: Envarsus contains lactose
Maltese: Envarsus fih lactose
English: Severe effects may occur, including allergic and anaphylactic reactions.
Maltese: Jistgħu jseħħu effetti severi, inkluż reazzjonijiet allerġiċi u anafilattiċi.
English: Envarsus is a prolonged-release formulation of tacrolimus resulting in an extended oral absorption profile with an average time to maximum blood concentration (Cmax) of approximately 6 hours (tmax) at steady state.
Maltese: Envarsus huwa formulazzjoni ta' tacrolimus li terħi l-mediċina bil-mod li twassal għal profil ta' assorbiment orali estiż b'ħin medju sal-konċentrazzjoni massima fid-demm (Cmax) ta' madwar 6 sigħat (tmax) fi stat fiss.
English: Chiesi Farmaceutici S.p.A. Tel: + 39 0521 2791
Maltese: Puh/Tel: + 39 0521 2791
English: The relationship between tacrolimus trough levels (C24) and systemic exposure (AUC0-24) for Envarsus is similar to that of immediate-release tacrolimus.
Maltese: 7 (mg:mg), lesponiment sistemiku medju għal tacrolimus (AUC0-24) kien simili għal dak ta' tacrolimus li jerħi l mediċina b'mod immedjat.
English: Immune system disorders
Maltese: Disturbi fissistema endokrinarja xagħar eċċessiv
English: In rats, tacrolimus caused toxic effects to the nervous system and the eyes.
Maltese: Fil-firien, tacrolimus ikkawża effetti tossiċi fuq is-sistema nervuża u l-għajnejn.
English: Less than 1% of unchanged tacrolimus was detected in the urine and faeces, indicating that tacrolimus is almost completely metabolised prior to elimination bile being the principal route of elimination.
Maltese: tacrolimus mhux mibdul instab fl-awrina u fl-ippurgar, li jindika li tacrolimus hu kważi kompletament metabolizzat qabel ma jiġi eliminat: bil-bili bħala r-rotta prinċipali ta' eliminazzjoni.
English: Nervous system disorders headache, tremor nervous system disorders seizures, disturbances in consciousness, peripheral neuropathies, dizziness, paraesthesias and dysaesthesias, writing impaired encephalopathy, central nervous system haemorrhages and cerebrovascular accidents, coma, speech and language ab-normalities, paralysis and paresis, amnesia hypertonia myasthenia
Maltese: emorraġiji fissistema nervuża ċentrali u inċidenti ċerebrovaskulari , koma, anormalitajiet fid-diskors u fil lingwa, paraliżi u paresi, amnesija ipertonija mijastenija
English: The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of cytokine genes.
Maltese: Il-kumpless FKBP12-tacrolimus jintrabat b'mod speċifiku u kompetittiv ma' u jinibixxi calcineurin, li jwassal għall-inibizzjoni dipendenti mill-kalċju tar-rotot ta' transduzzjoni tas-sinjal taċ-ċelluli T, u b'hekk jipprevjeni t-transkrizzjoni ta' sett diskret ta' ġeni ċitokini.
English: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Maltese: Pazjenti li għandhom problemi ereditarji rari ta' intolleranza għal galactose, nuqqas totali ta' lactase jew malassorbiment ta' glucose-galactose m'għandhomx jieħdu dan il-prodott mediċinali. 4.5
English: The pharmacokinetics, efficacy and safety of Envarsus and tacrolimus immediate-release capsules, both in combination with corticosteroids were compared in 117 liver transplant recipients, of whom 88 received treatment with Envarsus.
Maltese: Il-farmakokinetika, l-effikaċja u s-sigurtà ta' Envarsus u kapsuli ta' tacrolimus li jerħu l-mediċina b'mod immedjat, it-tnejn flimkien ma' kortikosterojdi kienu mqabbla f'117-il riċevitur ta' trapjant talfwied, li minnhom 88 irċevew kura b'Envarsus.
English: A negative effect of tacrolimus on male fertility in the form of reduced sperm count and motility was observed in rats (see section 5.3).
Maltese: Fil-firien kien osservat effett negattiv ta' tacrolimus fuq il-fertilità maskili fil-forma ta' tnaqqis fl-għadd tal-isperma u motilità mnaqqsa (ara sezzjoni 5.3).
English: CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels Clinically, the following substances have been shown to increase tacrolimus blood levels: Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole, voriconazole and isavuconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir) or Hepatitis C Virus (HCV) protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), the pharmacokinetic enhancer cobicistat, and the tyrosine kinase inhibitors nilotinib and imatinib.
Maltese: Kienu osservati interazzjonijiet qawwija ma' sustanzi kontra l-fungi bħal ketoconazole, fluconazole, itraconazole, voriconazole u isavuconazole; l-antibijotiku macrolide erythromycin; inibituri tal protease tal-HIV (eż. ritonavir, nelfinavir, saquinavir) jew inibituri tal-protease tal-Virus tal-Epatite Ċ
English: Envarsus therapy should commence at a dose of 0.11-0.13 mg/kg/day administered once daily in the morning.
Maltese: Terapija ta' Envarsus għandha tinbeda b'doża ta' 0.11-0.13 mg/kg/kuljum mogħtija darba kuljum filgħodu.
English: Injury, poisoning and procedural complications primary graft dysfunction
Maltese: Korriment, avvelenament u komplikazzjonij iet ta' xi proċedura disfunzjoni tattrapjant primarju
English: Envarsus 4 mg prolonged-release tablets tacrolimus
Maltese: Envarsus 4 mg pilloli li jerħu l-mediċina bil-mod tacrolimus
English: Envarsus 0.75 mg prolonged-release tablets Each prolonged-release tablet contains 0.75 mg tacrolimus (as monohydrate).
Maltese: U KWANTITATTIVA Envarsus 0.75 mg pilloli li jerħu l-mediċina bil-mod Kull pillola li terħi l-mediċina bil-mod fiha 0.75 mg tacrolimus (bħala monohydrate).